<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 29 Mar 2021 11:28:29 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>PD-L1/TGFβ/VEGF：道尔生物、启愈生物、恒瑞医药</title><link>https://mp.weixin.qq.com/s/o6cnSzPY_eyuWGFPV9qKmQ</link><description></description><content:encoded><![CDATA[PD-L1/TGFβ/VEGF：道尔生物、启愈生物、恒瑞医药]]></content:encoded><pubDate>Mon, 29 Mar 2021 10:32:11 +0800</pubDate></item><item><title>M7824之后TGFβ前路何在：整合素αvβ8更具潜力</title><link>https://mp.weixin.qq.com/s/kjZdxXcORgZejgUbQZKkfA</link><description></description><content:encoded><![CDATA[M7824之后TGFβ前路何在：整合素αvβ8更具潜力]]></content:encoded><pubDate>Sun, 28 Mar 2021 08:10:36 +0800</pubDate></item><item><title>永泰生物技术全梳理</title><link>https://mp.weixin.qq.com/s/6qW4s3gg2Dl_ecYkTLurZA</link><description></description><content:encoded><![CDATA[永泰生物技术全梳理]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>Nature：2026年ADC市场规模160亿美元，DS-8201超60亿美元</title><link>https://mp.weixin.qq.com/s/EKiqpjD1jOxKmnjHcgwNJA</link><description></description><content:encoded><![CDATA[Nature：2026年ADC市场规模160亿美元，DS-8201超60亿美元]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>1比19：FDA专家委员会拒绝批准NGF抗体Tanezumab</title><link>https://mp.weixin.qq.com/s/qmSlnqYGHQWkK_X6-gr3kQ</link><description></description><content:encoded><![CDATA[1比19：FDA专家委员会拒绝批准NGF抗体Tanezumab]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>Nature：反义寡核苷酸药物（ASO）综述与展望</title><link>https://mp.weixin.qq.com/s/Hg2n4utLCS2ly7WbK-ukOQ</link><description></description><content:encoded><![CDATA[Nature：反义寡核苷酸药物（ASO）综述与展望]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>Science：发现袋鼠第3种T细胞，γμT细胞</title><link>https://mp.weixin.qq.com/s/12M3l_qsU7Grlt2AX6iZlg</link><description></description><content:encoded><![CDATA[Science：发现袋鼠第3种T细胞，γμT细胞]]></content:encoded><pubDate>Fri, 26 Mar 2021 08:58:51 +0800</pubDate></item><item><title>华夏英泰：STAR-T对于实体瘤极具潜力</title><link>https://mp.weixin.qq.com/s/_x0Uz8PXpyEV9awshETtCQ</link><description></description><content:encoded><![CDATA[华夏英泰：STAR-T对于实体瘤极具潜力]]></content:encoded><pubDate>Thu, 25 Mar 2021 10:08:41 +0800</pubDate></item><item><title>三特异性CAR-T：CD19/CD20/CD22</title><link>https://mp.weixin.qq.com/s/pkqH_fLbKBpBpKEqAEqe5g</link><description></description><content:encoded><![CDATA[三特异性CAR-T：CD19/CD20/CD22]]></content:encoded><pubDate>Thu, 25 Mar 2021 10:08:41 +0800</pubDate></item><item><title>百奥泰二次递表港股IPO：ADC全军覆没之后，强化双抗布局</title><link>https://mp.weixin.qq.com/s/rNnYXXuPHrgNVBqba6Xknw</link><description></description><content:encoded><![CDATA[百奥泰二次递表港股IPO：ADC全军覆没之后，强化双抗布局]]></content:encoded><pubDate>Tue, 23 Mar 2021 23:27:14 +0800</pubDate></item><item><title>盘点三地上市的中国生物医药企业</title><link>https://mp.weixin.qq.com/s/hxwB9S7PMRMMHncD5LRfVA</link><description></description><content:encoded><![CDATA[盘点三地上市的中国生物医药企业]]></content:encoded><pubDate>Tue, 23 Mar 2021 10:42:36 +0800</pubDate></item><item><title>抑制性白细胞免疫球蛋白样受体：LILRB</title><link>https://mp.weixin.qq.com/s/6l-81xplg9DPpIPLNx0EeA</link><description></description><content:encoded><![CDATA[抑制性白细胞免疫球蛋白样受体：LILRB]]></content:encoded><pubDate>Tue, 23 Mar 2021 10:42:36 +0800</pubDate></item><item><title>大分子CDMO乘风破浪：原核、抗体、基因治疗</title><link>https://mp.weixin.qq.com/s/QDdzmuawFXYE6ZmTHm5YAQ</link><description></description><content:encoded><![CDATA[大分子CDMO乘风破浪：原核、抗体、基因治疗]]></content:encoded><pubDate>Mon, 22 Mar 2021 13:19:48 +0800</pubDate></item><item><title>康乃德今日美股上市，首日股价上涨30%</title><link>https://mp.weixin.qq.com/s/zjLfMJhA1juBr9euYdf3KA</link><description></description><content:encoded><![CDATA[康乃德今日美股上市，首日股价上涨30%]]></content:encoded><pubDate>Fri, 19 Mar 2021 23:15:22 +0800</pubDate></item><item><title>CAR-M完成首例给药，进军HER2实体瘤</title><link>https://mp.weixin.qq.com/s/A7ETqVSZ-E0v2Pxi33p0ag</link><description></description><content:encoded><![CDATA[CAR-M完成首例给药，进军HER2实体瘤]]></content:encoded><pubDate>Fri, 19 Mar 2021 07:07:07 +0800</pubDate></item><item><title>上交大医疗未来领袖第五期，打造独一无二的价值课程和平台</title><link>https://mp.weixin.qq.com/s/V6q65dGKGFXexp6yDEAATQ</link><description></description><content:encoded><![CDATA[上交大医疗未来领袖第五期，打造独一无二的价值课程和平台]]></content:encoded><pubDate>Fri, 19 Mar 2021 07:07:07 +0800</pubDate></item><item><title>Nature：预计年内超15款PROTAC进入临床</title><link>https://mp.weixin.qq.com/s/qoVHyTJd6lc44sYiKdd6mQ</link><description></description><content:encoded><![CDATA[Nature：预计年内超15款PROTAC进入临床]]></content:encoded><pubDate>Fri, 19 Mar 2021 07:07:07 +0800</pubDate></item><item><title>Christopher Garcia开发偏向性IL-10，或可用于自身免疫病</title><link>https://mp.weixin.qq.com/s/sj9DtI0lDlSHM9ANoC5k9A</link><description></description><content:encoded><![CDATA[Christopher Garcia开发偏向性IL-10，或可用于自身免疫病]]></content:encoded><pubDate>Fri, 19 Mar 2021 07:07:07 +0800</pubDate></item><item><title>国内首个：嘉和生物CD3/CD20双抗申报临床</title><link>https://mp.weixin.qq.com/s/ia6OjJd3ygb5IpNnfkNVHg</link><description></description><content:encoded><![CDATA[国内首个：嘉和生物CD3/CD20双抗申报临床]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>CCR8 目前尚无一例进入临床的热门靶点？</title><link>https://mp.weixin.qq.com/s/2Ri9UqqOvWYkkS2mxKkh7Q</link><description></description><content:encoded><![CDATA[CCR8 目前尚无一例进入临床的热门靶点？]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item></channel></rss>